Uncovering Minimal Pathways in Melanoma Initiation
H. Xiao, J. Shiu, C.-F. Chen, J. Wu, P. Zhou, S. S. Telang, R. Ruiz-Vega, A. D. Lander, A. K. Ganesan
Abstract
Cutaneous melanomas are clinically and histologically heterogeneous. Most display activating mutations in Braf or Nras and complete loss of function of one or more tumor suppressor genes. Mouse models that replicate such mutations produce fast-growing, pigmented tumors. However, mice that combine Braf activation with only heterozygous loss of Pten also produce tumors and, as we show here, in an Albino background this occurs even with Braf activation alone. Such tumors arise rarely, grow slowly, and express low levels of pigmentation genes. The timing of their appearance was consistent with a single step stochastic event, but no evidence could be found that it required de novo mutation, suggesting instead the involvement of an epigenetic transition. Single-cell transcriptomic analysis revealed such tumors to be heterogeneous, including a minor cell type we term LNM (Low-pigment, Neural- and extracellular Matrix-signature) that displays gene expression resembling "neural crest"-like cell subsets detected in the fast-growing tumors of more heavily-mutated mice, as well as in human biopsy and xenograft samples. We provide evidence that LNM cells pre-exist in normal skin, are expanded by Braf activation, can transition into malignant cells, and persist with malignant cells through multiple rounds of transplantation. We discuss the possibility that LNM cells not only serve as a pre-malignant state in the production of some melanomas, but also as an important intermediate in the development of drug resistance.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Functional differences drive the selection of NRAS mutants in melanoma
B. M. Murphy, T. J. Weiss, … C. E. Burd·bioRxiv·Jan 15, 2021
- BRN2 is a non-canonical melanoma tumor-suppressor
- Tumorigenesis driven by the BRAF V600E oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion
s. gadal, J. A. Boyer, … N. Rosen·bioRxiv·Nov 21, 2023
- UVB mutagenesis differs in NRAS- and BRAF-mutant mouse models of melanoma
R. L. Bowman, R. C. Hennessey, … C. E. Burd·bioRxiv·Dec 27, 2020
- Bidirectional interconversion between mutually exclusive tumorigenic and drug-tolerant melanoma cell phenotypes
Y. Zhang, R. L. Belote, … R. L. Judson-Torres·bioRxiv·Aug 26, 2020
- BMP-dependent oligoclonal cancer attractor state precedes neural crest fate in melanoma initiation
Alicia M. McConnell, Maggie H. Chassé, … Leonard Ira Zon·bioRxiv·Oct 22, 2024